Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Revenue (2021 - 2025)

Oncology Institute's Revenue history spans 5 years, with the latest figure at $142.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 41.58% year-over-year to $142.0 million; the TTM value through Dec 2025 reached $502.7 million, up 27.79%, while the annual FY2025 figure was $502.7 million, 27.79% up from the prior year.
  • Revenue reached $142.0 million in Q4 2025 per TOI's latest filing, up from $136.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $142.0 million in Q4 2025 to a low of $48.6 million in Q1 2021.
  • Average Revenue over 5 years is $83.8 million, with a median of $81.1 million recorded in 2023.
  • The largest YoY upside for Revenue was 41.58% in 2025 against a maximum downside of 10.29% in 2025.
  • A 5-year view of Revenue shows it stood at $52.3 million in 2021, then surged by 36.56% to $71.4 million in 2022, then grew by 20.11% to $85.8 million in 2023, then grew by 16.88% to $100.3 million in 2024, then skyrocketed by 41.58% to $142.0 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Revenue are $142.0 million (Q4 2025), $136.6 million (Q3 2025), and $119.8 million (Q2 2025).